Bile Acid Sequestrants Market Size

Bile Acid Sequestrants Market size is expected to reach USD 31 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of bile acid sequestrants was over USD 19 Billion. The increasing frequency of hyperlipidemia worldwide will drive the market in the anticipated period. Between 2017 and 2020, 10% of adults age 20 or older worldwide had entire hyperlipidemia cases above 240 mg/dL and about 17% had high-density lipoprotein (HDL, or “good”) cholesterol levels below 40 mg/dL. The entire frequency of hyperlipidemia was 33.8%, with the following risk values: triglyceride (TG), 12.8%; hypercholesterolemia, 16.1%; high-density lipoprotein cholesterol (cHDL), 15.0%; and low-density lipoprotein cholesterol (cLDL), 42.2%.

Another factor that is set to increase the revenue rate of the bile acid sequestrants market further is the continuous research and development in this field of bile acid sequestrants globally. For example, the Gastrointestinal Drugs Advisory Committee of the FDA on May 19, 2023, voted 12-2 that the 25-mg dose of OCA, a bile acid sequestrant does not outbalance the risks of drug-inspired liver injury notwithstanding modifications in liver damaging that were showed in the REGENERATE trial. The committee also suggested against speeding up licensing for OCA, recommending the FDA mark time to look for extra data from an ongoing phase 3 trial. Some bile acid sequestrants are also FDA-licensed for adolescents (10 to 17 years of age). Moreover, bile acid sequestrants are one of the few drugs secure for kids with allelomorphic familial hypercholesterolemia. Various research is still ongoing to understand the effect of bile acid sequestrants on other chronic diseases.